Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
Spinal ganglioglioma is a rare low-grade, slow-growing tumor of the central nervous system affecting mostly children and young adults. After surgery, some patients show tumor recurrence and/or malignant transformation. Gangliogliomas harbor molecular deficiencies such as mutations in the B-rapidly a...
Main Authors: | Louis Garnier, François Ducray, Clotilde Verlut, Marcella-Ionela Mihai, Françoise Cattin, Antoine Petit, Elsa Curtit |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00177/full |
Similar Items
-
The clinicopathological features of ganglioglioma with CD34 expression and BRAF mutation in patients with epilepsy
by: Ming-Guo Xie, et al.
Published: (2023-02-01) -
Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01) -
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01) -
INTEROBSERVER VARIABILITY REGARDING KI67 PROLIFERATION INDEX EVALUATION IN GANGLIOGLIOMA AND ANAPLASTIC GANGLIOGLIOMA
by: Antonia C. LISIEVICI, et al.
Published: (2021-06-01) -
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)